Capricor Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Capricor's estimated annual revenue is currently $20.3M per year.(i)
  • Capricor's estimated revenue per employee is $155,000

Employee Data

  • Capricor has 131 Employees.(i)
  • Capricor grew their employee count by 32% last year.

Capricor's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
EVP, General CounselReveal Email/Phone
3
VP, Head Research & Product DevelopmentReveal Email/Phone
4
VP QualityReveal Email/Phone
5
VP Clinical OperationsReveal Email/Phone
6
VP Program Management and Business OperationsReveal Email/Phone
7
VP Research and DevelopmentReveal Email/Phone
8
VP Clinical DevelopmentReveal Email/Phone
9
VP QualityReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$63.2M25235%N/AN/A
#2
$1.2M14N/AN/AN/A
#3
$25.3M101-9%N/AN/A
Add Company

What Is Capricor?

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac cell therapy. CAP-1002 consists of cardiosphere-derived cells, or CDCs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system's activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are now focused on developing a precision-engineered exosome platform technology that can carry defined sets of effector molecules including nucleic acids which exert their effects through defined mechanisms of action. We have begun work on our expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases.

keywords:N/A

N/A

Total Funding

131

Number of Employees

$20.3M

Revenue (est)

32%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Capricor News

2022-03-22 - Capricor Therapeutics Shares Tumble on Covid-19 Study Update CAPR

Capricor is currently developing CAP-1002 for the treatment of Duchenne muscular dystrophy, a rare, fatal neuromuscular genetic disease, and...

2022-03-22 - Capricor Therapeutics down 24% following COVID-19 mid-stage trial results (updated)

A phase 2 trial of Capricor Therapeutics' (CAPR -24.8%) COVID-19 treatment CAP-1002 met its primary objective of safety.

2022-03-22 - Capricor Therapeutics Reports Topline Results from Phase 2 ...

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-. SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.6M131-1%N/A
#2
$17M131-8%$20.4M
#3
$27.5M131-9%N/A
#4
$26.9M131-1%$79.8M
#5
$32.9M1318%N/A